Company profile: Incyclix Bio
1.1 - Company Overview
Company description
- Provider of small molecule CDK inhibitors for the treatment of advanced and resistant cancers, including INX-315, a selective CDK2 inhibitor in clinical development that targets abnormal cell proliferation.
Products and services
- Advanced Cancer CDK Therapeutics: Produces small-molecule CDK inhibitors (oncology-focused) intended for advanced and resistant cancers by directly disrupting abnormal cell proliferation pathways
- INX-315: A selective small-molecule CDK2 inhibitor (custom-engineered), in clinical development, that suppresses abnormal cell proliferation to treat advanced and resistant cancers via precise kinase targeting
- Small-Molecule CDK Inhibitor R&D: Develops cyclin-dependent kinase inhibitors (precision-engineered) targeting proliferation drivers in advanced and resistant cancers, emphasizing selectivity and small-molecule modalities per company focus
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Incyclix Bio
ElsaLys Biotech
HQ: France
Website
- Description: Provider of therapeutic monoclonal antibody development, based in Lyon and Illkirch Graffenstaden, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ElsaLys Biotech company profile →
Ajax Therapeutics
HQ: United States
Website
- Description: Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with Schrödinger using advanced computational chemistry and structure-based technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ajax Therapeutics company profile →
Ratio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ratio Therapeutics company profile →
Living Pharma
HQ: United States
Website
- Description: Provider of Personalized CAR T Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Living Pharma company profile →
Medivation
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on rapid development of small‑molecule drugs to treat serious diseases with limited treatment options, including the development of MDV3100 for multiple stages of advanced prostate cancer in collaboration with Astellas Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medivation company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Incyclix Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Incyclix Bio
2.2 - Growth funds investing in similar companies to Incyclix Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Incyclix Bio
4.2 - Public trading comparable groups for Incyclix Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →